Chronic inflammatory demyelinating polyneuropathy responsive to mycophenolate mofetil therapy

Gurdesh Bedi, Andrew Brown, Tao Tong, Khema R Sharma

Research output: Contribution to journalArticle

23 Citations (Scopus)

Abstract

Objective: To evaluate the efficacy of mycophenolate mofetil (MMF) in chronic inflammatory demyelinating polyneuropathy (CIDP). Background: Evidence is growing that MMF is effective as an immunomodulatory drug in neuromuscular diseases. Methods: A database of 184 patients with CIDP was analysed to obtain clinical, laboratory and electrophysiological information for patients with CIDP treated with MMF. Results: Eight patients, who met the inclusion criteria, received MMF (mean dose 2 g/day; median duration 15.2 months). The average Neuropathy Impairment Score of the eight patients improved from baseline (72.3±635) after initiation of MMF therapy (37.8±37; p<0.001). Six of these eight patients were either able to stop concomitant medications (corticosteroid, intravenous immunoglobulin) or reduce their doses and frequency by ≥50%. Conclusions: Our pilot data suggest that MMF appears to be an effective therapy for patients with naive or refractory CIDP, and further controlled studies are warranted for their confirmation.

Original languageEnglish
Pages (from-to)634-636
Number of pages3
JournalJournal of Neurology, Neurosurgery and Psychiatry
Volume81
Issue number6
DOIs
StatePublished - Jun 1 2010

Fingerprint

Chronic Inflammatory Demyelinating Polyradiculoneuropathy
Mycophenolic Acid
Therapeutics
Neuromuscular Diseases
Intravenous Immunoglobulins
Adrenal Cortex Hormones
Databases
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Clinical Neurology
  • Psychiatry and Mental health
  • Surgery

Cite this

Chronic inflammatory demyelinating polyneuropathy responsive to mycophenolate mofetil therapy. / Bedi, Gurdesh; Brown, Andrew; Tong, Tao; Sharma, Khema R.

In: Journal of Neurology, Neurosurgery and Psychiatry, Vol. 81, No. 6, 01.06.2010, p. 634-636.

Research output: Contribution to journalArticle

@article{3e7dfbceba744e5886df417ecda63b08,
title = "Chronic inflammatory demyelinating polyneuropathy responsive to mycophenolate mofetil therapy",
abstract = "Objective: To evaluate the efficacy of mycophenolate mofetil (MMF) in chronic inflammatory demyelinating polyneuropathy (CIDP). Background: Evidence is growing that MMF is effective as an immunomodulatory drug in neuromuscular diseases. Methods: A database of 184 patients with CIDP was analysed to obtain clinical, laboratory and electrophysiological information for patients with CIDP treated with MMF. Results: Eight patients, who met the inclusion criteria, received MMF (mean dose 2 g/day; median duration 15.2 months). The average Neuropathy Impairment Score of the eight patients improved from baseline (72.3±635) after initiation of MMF therapy (37.8±37; p<0.001). Six of these eight patients were either able to stop concomitant medications (corticosteroid, intravenous immunoglobulin) or reduce their doses and frequency by ≥50{\%}. Conclusions: Our pilot data suggest that MMF appears to be an effective therapy for patients with naive or refractory CIDP, and further controlled studies are warranted for their confirmation.",
author = "Gurdesh Bedi and Andrew Brown and Tao Tong and Sharma, {Khema R}",
year = "2010",
month = "6",
day = "1",
doi = "10.1136/jnnp.2009.177576",
language = "English",
volume = "81",
pages = "634--636",
journal = "Journal of Neurology, Neurosurgery and Psychiatry",
issn = "0022-3050",
publisher = "BMJ Publishing Group",
number = "6",

}

TY - JOUR

T1 - Chronic inflammatory demyelinating polyneuropathy responsive to mycophenolate mofetil therapy

AU - Bedi, Gurdesh

AU - Brown, Andrew

AU - Tong, Tao

AU - Sharma, Khema R

PY - 2010/6/1

Y1 - 2010/6/1

N2 - Objective: To evaluate the efficacy of mycophenolate mofetil (MMF) in chronic inflammatory demyelinating polyneuropathy (CIDP). Background: Evidence is growing that MMF is effective as an immunomodulatory drug in neuromuscular diseases. Methods: A database of 184 patients with CIDP was analysed to obtain clinical, laboratory and electrophysiological information for patients with CIDP treated with MMF. Results: Eight patients, who met the inclusion criteria, received MMF (mean dose 2 g/day; median duration 15.2 months). The average Neuropathy Impairment Score of the eight patients improved from baseline (72.3±635) after initiation of MMF therapy (37.8±37; p<0.001). Six of these eight patients were either able to stop concomitant medications (corticosteroid, intravenous immunoglobulin) or reduce their doses and frequency by ≥50%. Conclusions: Our pilot data suggest that MMF appears to be an effective therapy for patients with naive or refractory CIDP, and further controlled studies are warranted for their confirmation.

AB - Objective: To evaluate the efficacy of mycophenolate mofetil (MMF) in chronic inflammatory demyelinating polyneuropathy (CIDP). Background: Evidence is growing that MMF is effective as an immunomodulatory drug in neuromuscular diseases. Methods: A database of 184 patients with CIDP was analysed to obtain clinical, laboratory and electrophysiological information for patients with CIDP treated with MMF. Results: Eight patients, who met the inclusion criteria, received MMF (mean dose 2 g/day; median duration 15.2 months). The average Neuropathy Impairment Score of the eight patients improved from baseline (72.3±635) after initiation of MMF therapy (37.8±37; p<0.001). Six of these eight patients were either able to stop concomitant medications (corticosteroid, intravenous immunoglobulin) or reduce their doses and frequency by ≥50%. Conclusions: Our pilot data suggest that MMF appears to be an effective therapy for patients with naive or refractory CIDP, and further controlled studies are warranted for their confirmation.

UR - http://www.scopus.com/inward/record.url?scp=77953712395&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77953712395&partnerID=8YFLogxK

U2 - 10.1136/jnnp.2009.177576

DO - 10.1136/jnnp.2009.177576

M3 - Article

VL - 81

SP - 634

EP - 636

JO - Journal of Neurology, Neurosurgery and Psychiatry

JF - Journal of Neurology, Neurosurgery and Psychiatry

SN - 0022-3050

IS - 6

ER -